KAS
KRYS icon

Kemnay Advisory Services’s Krystal Biotech KRYS Stock Holding History

Kemnay Advisory Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.8K Buy
216
+132
+157% +$35.1K 0.01% 229
2025
Q4 		$20.7K Buy
+84
New +$17.7K ﹤0.01% 533

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kemnay Advisory Services's KRYS Position: Q1 2026 in Review

Kemnay Advisory Services increased its Krystal Biotech (KRYS) stake by 157% in Q1 2026, buying an estimated $35.1K and bringing the position to 216 shares worth $55.8K. The position accounts for 0.01% of the portfolio, ranked #229.

Kemnay Advisory Services first reported a position in KRYS in Q4 2025 and has held it in 2 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Kemnay Advisory Services held 216 shares of Krystal Biotech worth $55.8K as of Q1 2026.
  • Kemnay Advisory Services bought 132 Krystal Biotech shares in Q1 2026, an estimated $35.1K.
  • Krystal Biotech made up 0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #229 holding.
  • Kemnay Advisory Services first reported a position in Krystal Biotech in Q4 2025 and has held it in 2 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.